GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 66.10B |
| Revenue (ttm) | 31.63B |
| Net Income (ttm) | 3.42B |
| Shares Out | 4.02B |
| EPS (ttm) | 0.83 |
| PE Ratio | 19.90 |
| Forward PE | 9.59 |
| Dividend | 0.61 (3.72%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 7,925,128 |
| Average Volume | 9,117,482 |
| Open | 1,624.50 |
| Previous Close | 1,640.00 |
| Day's Range | 1,624.50 - 1,660.50 |
| 52-Week Range | 1,242.50 - 1,684.50 |
| Beta | 0.29 |
| RSI | 61.43 |
| Earnings Date | Oct 29, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep
On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE: GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients wit...
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
GSK shares fall as narrow approval of blood cancer drug limits US relaunch
GSK's London-listed shares fell nearly 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...
GSK Announces FDA Approval Of Blenrep
(RTTNews) - GSK plc (GSK, GSK.L) announced the FDA has approved Blenrep in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myelom...
GSK's Blenrep Reapproved by FDA for Blood Cancer Treatment
GSK's Blenrep Reapproved by FDA for Blood Cancer Treatment
FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK
The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
PHILADELPHIA--(BUSINESS WIRE)-- #BelantamabMafodotin--Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma.
GSK (GSK) Gains FDA Nod for Blenrep's Return as Multiple Myeloma Treatment
GSK (GSK) Gains FDA Nod for Blenrep's Return as Multiple Myeloma Treatment
FDA Greenlights GSK's Blenrep for Advanced Multiple Myeloma
FDA Greenlights GSK's Blenrep for Advanced Multiple Myeloma
GSK wins FDA approval of Blenrep for multiple myeloma
US FDA approve GSK's blood cancer treatment
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch...
GSK's New Inhaler Formula Shows Positive Phase III Results
GSK's New Inhaler Formula Shows Positive Phase III Results
GSK : Latozinemab Fails To Meet Clinical Endpoint In INFRONT-3 FTD-GRN Trial
(RTTNews) - GSK plc. (GSK, GSK.L) and Alector, Inc. announced results from the INFRONT-3 clinical trial evaluating latozinemab in individuals with frontotemporal dementia caused by a mutation in the p...
Here's Why GSK (GSK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK Receives Positive EMA Opinion for Shingrix Prefilled Syringe
GSK Receives Positive EMA Opinion for Shingrix Prefilled Syringe
GSK (GSK) Announces Promising Results for Tebipenem HBr in cUTI Trial
GSK (GSK) Announces Promising Results for Tebipenem HBr in cUTI Trial
GSK: CHMP Issues Positive Opinion On Shingrix In Prefilled Syringe
(RTTNews) - GSK plc (GSK, GSK.L) announced that the European Medicine Agency's CHMP has issued a positive opinion to support the approval of Shingrix in a prefilled syringe. Currently, the vaccine pre...
Astra, GSK up after report on U.K. – U.S. drug pricing deal
AstraZeneca (AZN) stock and GSK (GSK) stock gain as the U.K. and U.S. are reportedly clining in on a major drug pricing deal. Read more here.
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE: GSK), Pfizer Inc (NYSE: PFE) and Shionogi Inc . NICE has r...
GSK's Niraparib Receives FDA Orphan Drug Status for Malignant Glioma
GSK's Niraparib Receives FDA Orphan Drug Status for Malignant Glioma
GSK's HIV Treatment Dovato Shows Promising 96-Week Results
GSK's HIV Treatment Dovato Shows Promising 96-Week Results
UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug
The UK's drugs cost-effectiveness watchdog has given a positive recommendation for ViiV Healthcare's HIV drug, enabling access to the preventive medicine via the state health system in England and Wal...
GSK (GSK) Involvement in FDA's Leucovorin Label Update Explained
GSK (GSK) Involvement in FDA's Leucovorin Label Update Explained
Pfizer (PFE) and GSK's ViiV Shows Promising HIV Therapy Results
Pfizer (PFE) and GSK's ViiV Shows Promising HIV Therapy Results
SCYNEXIS (SCYX) Secures $22 Million from GlaxoSmithKline Settlement
SCYNEXIS (SCYX) Secures $22 Million from GlaxoSmithKline Settlement